SCHEMBL1810653

SCHEMBL1810653

NCCCCCC(=O)Nc1ccc(B(O)O)cc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
HDAC1 Q13547 5/20 0.44
HDAC3 O15379 4/20 0.41
HDAC2 Q92769 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NCOR2 Q9Y618 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
KAT2B Q92831 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.40
CRHBP P24387 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1938193 0.80 RAB9A (0.67) RAB9ANPC1HDAC1HDAC3HDAC2
SCHEMBL7188519 0.76 HDAC1 (0.48) RAB9ANPC1HDAC1HDAC3HDAC2
SCHEMBL13650005 0.75 MAPT (0.61) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL7866816 0.73 RAB9A (0.47) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL8919802 0.73 RAB9A (0.51) RAB9ANPC1HDAC1HDAC3MEN1
SCHEMBL7866812 0.73 RAB9A (0.47) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL16634476 0.72 ALDH1A1 (0.47) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL16387330 0.72 HDAC1 (0.55) HDAC1HDAC3HDAC2MEN1KMT2A
SCHEMBL23088816 0.70 SNCA (0.43) MEN1KMT2AMAPT
SCHEMBL29758188 0.70 SNCA (0.43) MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11110119-B2 Bi-functional co-polymer use for ophthalmic and other topical and local applications CALM WATER THERAPEUTICS LLC (US) 2021-09-07 US claimed
US-20200352984-A1 Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications CALM WATER THERAPEUTICS LLC 2020-11-12 US claimed
US-10729715-B2 Bi-functional co-polymer use for ophthalmic and other topical and local applications EYEON PARTICLE SCIENCES LLC (US) 2020-08-04 US claimed
US-20180161363-A1 Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications CALM WATER THERAPEUTICS LLC 2018-06-14 US claimed
US-9884074-B2 Bi-functional co-polymer use for ophthalmic and other topical and local applications EYEON PARTICLE SCIENCES LLC (US) 2018-02-06 US claimed
EP-3246048-A1 BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS Eyeon Particle Sciences LLC (US) 2017-11-22 EP claimed
US-20160243156-A1 Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications CALM WATER THERAPEUTICS LLC 2016-08-25 US claimed
US-9283248-B2 Bi-functional co-polymer use for ophthalmic and other topical and local applications EYEON PARTICLE SCIENCES LLC (US) 2016-03-15 US claimed
US-7029688-B2 Methods and compositions to prevent formation of adhesions in biological tissues CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2006-04-18 US claimed
EP-1009451-B1 COMPOSITIONS AND THEIR USE TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INST OF TECHN (US) 2003-10-29 EP claimed
US-20030185787-A1 Methods and compositions to prevent formation of adhesions in biological tissues CALIFORNIA INSTITUTE OF TECHNOLOGY 2003-10-02 US claimed
US-6596267-B1 Such as ethylene glycol-phenylboronic acid copolymer; prosthetics and implant coatings; readily adsorbs onto body tissues in situ providing steric barrier minimizing post-operative adhesion CALIFORNIA INSTITUTE OF TECHNOLOGY 2003-07-22 US claimed
EP-1009451-A2 METHODS AND COMPOSITIONS TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-06-21 EP claimed
WO-1999010022-A2 METHODS AND COMPOSITIONS TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1999-03-04 WO claimed
US-20240117158-A1 COMPOSITIONS AND METHODS FOR TREATING A DISORDER OR DEFECT IN SOFT TISSUE UNIV DREXEL (US) 2024-04-11 US disclosed
US-20230355661-A1 BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS CALM WATER THERAPEUTICS LLC 2023-11-09 US disclosed
US-20220348745-A1 Compositions and Methods for Treating a Disorder or Defect in Soft Tissue UNIV DREXEL (US) 2022-11-03 US disclosed
EP-1009451-A2 METHODS AND COMPOSITIONS TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-06-21 EP disclosed
WO-2000012146-A1 GELS AND MULTILAYER SURFACE STRUCTURES FROM BORONIC ACID CONTAINING POLYMERS EIDGENÖSSISCH TECHNISCHE HOCHSCHULE ZURICH (CH) 2000-03-09 WO disclosed
WO-1999010022-A2 METHODS AND COMPOSITIONS TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030185787-A1 Methods and compositions to prevent formation of adhesions in biological tissues ITGB6, ITGA6, EPCAM RAB9A 1365/4885NPC1 3864/4885HDAC1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.